Eli Lilly logo
Research results have shown that Eli Lilly’s obesity treatment drug “Zebbound” (ingredient name: tirzepatide) is effective in treating hypertension.
According to industry sources, the results of “SURMOUNT-1”, a phase 3 clinical trial evaluating the effectiveness of Zebbound in the treatment of obesity, were recently published in the American Heart Association’s academic journal “Hypertension”.
Researchers at the University of Texas Southwestern Medical Center in the US measured ambulatory blood pressure 24 hours a day for 36 weeks in 600 obese patients without diabetes to confirm the correlation between Zebbound and blood pressure. Of these, 30% suffered from high blood pressure and 29% were taking one or more antihypertensive drugs.
They were given a placebo (fake medicine) or tirzepatide (5, 10 and 15 mg) once a week. 155 people received placebo, 145 people received Zebbound 5 mg, 152 people received 10 mg, and 148 people received 15 mg.
As a result, at week 36, the Zebbound 5 mg group’s systolic blood pressure was reduced by an average of 7.4 mm Hg, the 10 mg group was reduced by an average of 10.6 mm Hg, and the Zebbound 5 mg group 15 mg was reduced by an average of 8.0 mm Hg.
Furthermore, according to the study, the blood pressure-lowering effect of tirzepatide was demonstrated consistently across participant groups during both the day and night (day and night). Nocturnal systolic blood pressure is known to be a more accurate predictor of cardiovascular disease-related death than daytime systolic blood pressure.
As a result of the drug correlation analysis, the researchers did not confirm whether the blood pressure-lowering effect of tirzepatide was due to weight loss or the drug, but explained that the blood pressure-lowering effect was similar to that of other antihypertensive drugs.
However, he added that more research is needed to determine the long-term effects on heart attacks, heart failure and cardiovascular problems. It was also stated that research into changes in blood pressure after stopping the drug was needed.
Tirzepatide is a drug with dual action on GLP-1 (glucagon-like peptide 1) and another hormone, GIP (glucose-dependent insulinotropic polypeptide), to control blood sugar levels in patients with type 2 diabetes. It has received approval from the United States. Food and Drug Administration (FDA) as a treatment. However, since it was confirmed in clinical trials to be more effective in treating obesity than existing drugs, it was also approved as an obesity treatment through further clinical trials.
Eli Lilly announced that in the Phase 3 Zebbound clinical trial, administration of 15 mg of Zebbound for 72 weeks resulted in weight loss of up to 22.5%. In the 84-week clinical dosing study, body weight was reduced by an average of 26.6%.
Meanwhile, due to the obesity treatment that has become a global sensation since last year, Eli Lilly’s sales of Tirzepatide for diabetes and obesity last year reached $5.1631 billion (approximately 6.7 trillion KRW), more than 10 times higher than in 2022. . .
#Eli #Lillys #obesity #treatment #drug #Zebbound #blood #pressurelowering #effects
